-
Team - Diadem DX
Team
CEO
Paul has over 30 years of experience in the global life sciences industry, with the past 20 years of his executive career focused on Clinical Diagnostics and innovative products to improve ...
-
About - Diadem DX
About
33 Million Alzheimer dementia patients worldwide
152 Million dementia patients estimated by 2050
US $1 Trillion estimated global annual cost of dementia
%
ABOUT DIADEM
is to enable prediction,...
-
News - Diadem DX
News
NEWS
Milan, Italy and Amsterdam, Netherlands, July 19, 2023
Diadem srl, a company developing the first blood-based test for the early prediction of clinical progression to Alzheimer’s disease (AD...
-
Alzosure Predict - Diadem DX
Alzosure Predict
ALZOSURE® PREDICT
AlzoSure® Predict is a simple, non-invasive blood test to predict the early onset of Alzheimer’s disease (AD) with the ability to identify mild cognitive impairment ...
-
Publications - Diadem DX
Publications
PUBLICATIONS
Impact of COVID-19 on Alzheimer’s Disease Risk: Viewpoint for Research Action. Healthcare (Basel). 2020 Aug 21;8(3):E286.
Abate G, Memo M, Uberti D.
A telescope GWAS ana...
-
MAB - Diadem DX
MAB
TAMAS BARTFAI
Ph.D.
Prof. Tamas Bartfai, Ph.D. , is an international leader and expert in the development of drugs targeting neurological diseases. Prof. Bartfai has been involved as a consultan...